Aimmune
European Commission approves EU’s first peanut allergy treatment
December 21, 2020Sales and Marketing Aimmune, European Commission, allergy
Aimmune Therapeutics today announced that the European Commission (EC) has approved PALFORZIA as the EU’s first-ever treatment of peanut allergy. …
Nestlé to acquire remaining shares in Aimmune for $2.6 billion
September 2, 2020Research and Development, Sales and Marketing Aimmune, acquisition, nestle, pharma
Food and drink giant Nestlé has confirmed it is in motion to scoop up the remaining shares in Californian biotech …
Aimmune’s peanut allergy therapy recommended for approval by FDA committee
September 16, 2019Sales and Marketing Aimmune, FDA, peanut allergy, pharma
The FDA’s Allergenic Products Advisory Committee (APAC) has recommended the use of Aimmune Therapeutics’ AR101, also known by its proposed …
Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data
March 26, 2019Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma
Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …
FDA halts allergy drug approval process due to government shutdown
January 15, 2019Research and Development Aimmune, FDA, Trump, governmetn, shutdown
California-based pharma firm, Aimunne Therapeutics has been notified that due to the government shutdown, the US Food and Drug Administration …
Aimmune’s peanut allergy candidate hits main endpoint at Phase 3
February 21, 2018Research and Development Aimmune, peanut, peanut allergy, pharma
US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
Peanut allergies? There’s a clinical trial looking to fix that
October 17, 2017Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical
Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …
Nestle backs allergy biotech Aimmune to the tune of $145 million
November 7, 2016Sales and Marketing Aimmune, allergy therapeutics, nestle
Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …
